Yi X Wang Y Lin J Cheng W Zhou Q Wang C.

Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates with Efficacy of Clopidogrel and Adverse Events on Patients with Ischemic Stroke.

Clin Appl Thromb. 23: 761-768https://doi.org/10.1177/1076029616648408Yi X Zhou Q Zhang Y Zhou J Lin J.

Variants in clopidogrel-relevant genes and early neurological deterioration in ischemic stroke patients receiving clopidogrel.

BMC Neurol. 20: 1-8https://doi.org/10.1186/s12883-020-01703-6Virani SS Alonso A Benjamin EJ Bittencourt MS Callaway CW Carson AP Chamberlain AM Chang AR Cheng S Delling FN Djousse L Elkind MSV Ferguson JF Fornage M Khan SS Kissela BM Knutson KL KT

2020 Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease.

Circulation. 141: 9-11Alakbarzade V Huang X Ster IC McEntagart M Pereira AC.

High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: Systematic review and meta-analysis.

J Stroke Cerebrovasc Dis. 29https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104877Yi X Lin J Zhou Q Wu L Cheng W Wang C.

Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population.

J Stroke Cerebrovasc Dis. 25: 1222-1228https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.02.013Wiśniewski A Filipska K.

The phenomenon of clopidogrel high on-treatment platelet reactivity in ischemic stroke subjects: A comprehensive review.

Int J Mol Sci. 21: 1-13https://doi.org/10.3390/ijms21176408Hasan MS Bin Basri H Hin LP Stanslas J

Genetic polymorphisms and drug interactions leading to clopidogrel resistance: Why the asian population requires special attention.

Int J Neurosci. 123: 143-154https://doi.org/10.3109/00207454.2012.744308Holmes M V Perel P Shah T Hingorani AD Casas JP.

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis.

JAMA - J Am Med Assoc. 306: 2704-2714Maruyama H Fukuoka T Deguchi I Ohe Y Horiuchi Y Kato Y et al.

Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients.

Intern Med. 53: 2575-2579https://doi.org/10.2169/internalmedicine.53.2918

Drug Insight: Clopidogrel nonresponsiveness.

Nat Clin Pract Cardiovasc Med. 3: 387-395https://doi.org/10.1038/ncpcardio0602Nguyen TA Diodati JG Pharand C.

Resistance to clopidogrel: A review of the evidence.

J Am Coll Cardiol. 45: 1157-1164https://doi.org/10.1016/j.jacc.2005.01.034Mega JL Simon T Collet JP Anderson JL Antman EM Bilden K et al.

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis.

JAMA - J Am Med Assoc. 304: 1821-1830https://doi.org/10.1001/jama.2010.1543.Reduced-Function

Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine.

J Pers Med. 8: 1-31https://doi.org/10.3390/jpm8010008

Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.

Front Genet. 3: 1-8https://doi.org/10.3389/fgene.2012.00206Amin AM Sheau Chin L Azri Mohamed Noor D Sk Abdul Kader MA Kah Hay Y Ibrahim B

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.

Cardiol Res Pract. ()https://doi.org/10.1155/2017/8062796Rao S. Uppugunduri C Daali Y Desmeules J Dayer P Krajinovic M Ansari M.

Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity.

Curr Drug Metab. 13: 1196-1204https://doi.org/10.2174/138920012802850146Sanford JC Guo Y Sadee W Wang D.

Regulatory polymorphisms in CYP2C19 affecting hepatic expression.

Drug Metabol Drug Interact. 28: 23-30https://doi.org/10.1515/dmdi-2012-0038Kheiri B Osman M Abdalla A Haykal T Pandrangi P V Chahine A et al.

CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.

Catheter Cardiovasc Interv. 93: 1246-1252https://doi.org/10.1002/ccd.27949Fu H Hu P Ma C Peng F He Z.

Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study.

Medicine (Baltimore). 99: e19472https://doi.org/10.1097/MD.0000000000019472Zhang L Yang J Zhu X Wang X Peng L Li X et al.

Effect of high-dose clopidogrel according to CYP2C19∗2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.

Thromb Res. 135: 449-458https://doi.org/10.1016/j.thromres.2014.12.007Pan Y Chen W Xu Y Yi X Han Y Yang Q et al.

Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack.

Circulation. 135: 21-33https://doi.org/10.1161/CIRCULATIONAHA.116.024913Anderson JL Mower C Horne BD.

Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel [abstract 27].

J Am Coll Cardiol. 53: 2903-2908Hoh BL Gong Y McDonough CW Waters MF Royster AJ Sheehan TO et al.

CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.

J Neurosurg. 124: 1746-1751https://doi.org/10.3171/2015.6.JNS15795

Bhatt D, Simonsen K, Emison E. CHARISMA genomics substudy: evaluation of the CYP2C19 polymorphism in a prospective, randomized, placebo-controlled trial of chronic clopidogrel use for primary and secondary prevention 2009.

Bhatt DL Paré G Eikelboom JW Simonsen KL Emison ES Fox KAA et al.

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The CHARISMA genetics study.

Eur Heart J. 33: 2143-2150https://doi.org/10.1093/eurheartj/ehs059Bonello L Armero S Mokhtar OA Mancini J Aldebert P Saut N et al.

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.

J Am Coll Cardiol. 56: 1630-1636https://doi.org/10.1016/j.jacc.2010.07.004Bouman HJ Schömig E Van Werkum JW Velder J Hackeng CM HirschhÄuser C et al.

Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Nat Med. 17: 110-116https://doi.org/10.1038/nm.2281Campo G Parrinello G Ferraresi P Lunghi B Tebaldi M Miccoli M et al.

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome.

J Am Coll Cardiol. 57: 2474-2483https://doi.org/10.1016/j.jacc.2010.12.047Cavallari LH Lee CR Beitelshees AL Cooper-DeHoff RM Duarte JD Voora D et al.

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

JACC Cardiovasc Interv. 11: 181-191https://doi.org/10.1016/j.jcin.2017.07.022Chen Y bei Zhou Z yi Li G min Xiao C xing Yu W bang Zhong S long et al.

Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients.

Acta Pharmacol Sin. 40: 762-768https://doi.org/10.1038/s41401-018-0178-4Collet JP Hulot JS Pena A Villard E Esteve JB Silvain J et al.

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Lancet. 373: 309-317https://doi.org/10.1016/S0140-6736(08)61845-0

Genetic polymorphism of CYP2C19 and inhibitory effects of ticagrelor and clopidogrel towards post-percutaneous coronary intervention (PCI) platelet aggregation in patients with acute coronary syndromes.

Med Sci Monit. 22: 4929-4936https://doi.org/10.12659/MSM.902120Fang L Zhao Y Wang N Yang Z Huang H Lin M.

Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 32 (): 871-876https://doi.org/10.3760/cma.j.issn.1003-9406.2015.06.026Fathy S Shahin MH Langaee T Khalil BM Saleh A Sabry NA et al.

Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.

Pharmacogenet Genomics. 28: 207-213https://doi.org/10.1097/FPC.0000000000000349Giusti B Gori AM Marcucci R Saracini C Sestini I Paniccia R et al.

Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis.

Am J Cardiol. 103: 806-811https://doi.org/10.1016/j.amjcard.2008.11.048González A Moniche F Cayuela A García-Lozano JR Torrecillas F Escudero-Martínez I et al.

Effect of CYP2C19 polymorphisms on the platelet response to clopidogrel and influence on the effect of high versus standard dose clopidogrel in carotid artery stenting.

Eur J Vasc Endovasc Surg. 51: 175-186https://doi.org/10.1016/j.ejvs.2015.09.020Harmsze AM Van Werkum JW Ten Berg JM Zwart B Bouman HJ Breet NJ et al.

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: A case-control study.

Eur Heart J. 31: 3046-3053https://doi.org/10.1093/eurheartj/ehq321Spokoyny I Barazangi N Jaramillo V Rose J Chen C Wong C et al.

Reduced clopidogrel metabolism in a multiethnic population: Prevalence and rates of recurrent cerebrovascular events.

J Stroke Cerebrovasc Dis. 23: 694-698https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.06.008Jeong YH Kim IS Park Y Kang MK Koh JS Hwang SJ et al.

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: Results of the ACCEL-DOUBLE (Accelerated platelet inhibition by a double dose of clopidogrel ac.

JACC Cardiovasc Interv. 3: 731-741https://doi.org/10.1016/j.jcin.2010.05.007Jia DM Bin Chen Z Zhang MJ Yang WJ Jin JL Xia YQ et al.

CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.

Stroke. 44: 1717-1719https://doi.org/10.1161/STROKEAHA.113.000823

Komarov A, Shakhmatova O, Donnikov A, Ilyushchenko T, Dzhalilova G, Panchenko E. Carrying of P450 2C19*2 polymorphism and use of proton pump inhibitors increase risk of adverse outcomes after elective PCI in Russian patients with CAD [abstract P491] 2011. https://doi.org/10.1177 /1741826711407011.

Kubica A Kasprzak M Obońska K Koziński M Navarese EP Grześk G et al.

Impact of CYP2C19 polymorphisms on antiplatelet efficacy of clopidogrel in patients after myocardial infarction.

Folia Medica Copernicana. 1: 12-17Lee CR Sriramoju VB Cervantes A Howell LA Varunok N Madan S et al.

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Circ Genomic Precis Med. 11e002069https://doi.org/10.1161/CIRCGEN.117.002069Li XQ Ma N Li XG Wang B Sen Sun S Gao F et al.

Association of PON1, P2Y12 and COX1 with recurrent ischemic events in patients with extracranial or intracranial stenting.

PLoS One. 11: 1-12https://doi.org/10.1371/journal.pone.0148891Lin YJ Li JW Zhang MJ Qian L Yang WJ Zhang CL et al.

The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment.

CNS Neurosci Ther. 20: 125-130https://doi.org/10.1111/cns.12173Lin J Han Z Wang C Yi X Chai Z Zhou Q et al.

Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.

Eur J Clin Pharmacol. 74: 1131-1140https://doi.org/10.1007/s00228-018-2468-7

The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention.

Medicine (Baltimore). 99: e19143https://doi.org/10.1097/MD.0000000000019143Luo Y Zhao YT Verdo A Qi WG Zhang D-F Hu B.

Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.

J Int Med Res. 39: 2012-2019https://doi.org/10.1177/147323001103900548Malek LA Kisiel B Spiewak M Grabowski M Filipiak KJ Kostrzewa G et al.

Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.

Circ J. 72: 1165-1169https://doi.org/10.1253/circj.72.1165Małek ŁA Przyłuski J Śpiewak M Kłopotowski M Kostrzewa G Kruk M et al.

Cytochrome P450 2C19 Polymorphism, Suboptimal Reperfusion and All-Cause Mortality in Patients with Acute Myocardial Infarction.

Cardiology. 117: 81-87Martin J Williams AK Klein MD Sriramoju VB Madan S Rossi JS et al.

Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.

Genet Med. 22: 160-169https://doi.org/10.1038/s41436-019-0611-1McDonough CW McClure LA Mitchell BD Gong Y Horenstein RB Lewis JP et al.

CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.

J Am Heart Assoc. 4e001652https://doi.org/10.1161/JAHA.114.001652Mega JL Thakuria J Cannon C Sabatine MS.

Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITYTIMI 28 genomic study.

J Am Coll Cardiol. 51: A206Mega JL Close SL Wiviott SD Shen L Hockett RD Brandt JT et al.

Cytochrome p-450 polymorphisms and response to clopidogrel.

N Engl J Med. 360: 354-362https://doi.org/10.1056/NEJMoa0809171Mega JL Hochholzer W Frelinger AL Kluk MJ Angiolillo DJ Kereiakes DJ et al.

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

JAMA - J Am Med Assoc. 306: 2221-2228https://doi.org/10.1001/jama.2011.1703Nishio R Shinke T Otake H Sawada T Haraguchi Y Shinohara M et al.

Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel.

Circ J. 76: 2348-2355https://doi.org/10.1253/circj.CJ-12-0476Ogawa H Isshiki T Kimura T Yokoi H Nanto S Takayama M et al.

Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.

J Cardiol. 68: 26-36https://doi.org/10.1016/j.jjcc.2015.07.019Oh IY Park KW Kang SH Park JJ Na SH Kang HJ et al.

Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.

Heart. 98: 139-144https://doi.org/10.1136/hrt.2011.227272Ono T Kaikita K Hokimoto S Iwashita S Yamamoto K Miyazaki Y et al.

Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.

Thromb Res. 128: e130-e136https://doi.org/10.1016/j.thromres.2011.07.028Paré G Mehta SR Yusuf S Anand SS Connolly SJ Hirsh J et al.

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

N Engl J Med. 363: 1704-1714Peng Y Chen M jing Liu X Liu W Li Q Chai H et al.

The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.

Atherosclerosis. 227: 106-111https://doi.org/10.1016/j.atherosclerosis.2012.12.028Price MJ Murray SS Angiolillo DJ Lillie E Smith EN Tisch RL et al.

Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: The GIFT (Genotype Information and Functional Testing) study.

J Am Coll Cardiol. 59: 1928-1937https://doi.org/10.1016/j.jacc.2011.11.068Qiu LN Sun Y Wang L Han RF Xia XS Liu J et al.

Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.

Eur J Pharmacol. 747: 29-35https://doi.org/10.1016/j.ejphar.2014.11.037Rao Z Zheng H Wang F Wang A Liu L Dong K et al.

The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.

Neurol Res. 39: 719-726https://doi.org/10.1080/01616412.2017.1312793Sreedharan S Churilov L Chan J Todaro M Coulthard A Hocking J et al.

Association between CYP2C9 polymorphisms and ischemic stroke following endovascular neurointervention.

J Stroke Cerebrovasc Dis. 29104901https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104901Zhang S Lai X Li W Jing Z Xiong Z Xu A et al.

VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke.

Thromb Res. 134: 1272-1277https://doi.org/10.1016/j.thromres.2014.10.001Sawada T Shinke T Shite J Honjo T Haraguchi Y Nishio R et al.

Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.

Circ J. 75: 99-105https://doi.org/10.1253/circj.CJ-10-0525Shen DL Wang B Bai J Han Q Liu C Huang XH et al.

Clinical Value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population.

J Cardiovasc Pharmacol. 67: 232-236https://doi.org/10.1097/FJC.0000000000000337Shuldiner AR O'Connell JR Bliden KP Gandhi A Ryan K Horenstein RB et al.

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

JAMA - J Am Med Assoc. 302: 849-858https://doi.org/10.1001/jama.2009.1232Sibbing D Stegherr J Latz W Koch W Mehilli J Dörrler K et al.

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

Eur Heart J. 30: 916-922https://doi.org/10.1093/eurheartj/ehp041Simon T Verstuyft C Mary-Krause M Quteineh L Drouet E Méneveau N et al.

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.

N Engl J Med. 360: 363-375https://doi.org/10.1056/nejmoa0808227Jeong TD Kim SM Kim HJ Lee W Kwon SU Min WK et al.

CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.

J Stroke Cerebrovasc Dis. 24: 440-446https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.09.014Tanaka T Yamagami H Ihara M Miyata T Miyata S Hamasaki T et al.

Association of CYP2C19 polymorphisms with clopidogrel reactivity and clinical outcomes in chronic ischemic stroke.

Circ J. 83: 1385-1393https://doi.org/10.1253/circj.CJ-18-1386Tang X-F He C Yuan J-Q Meng X-M Yang Y-J Qin X-W et al.

Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention.

Zhonghua Xin Xue Guan Bing Za Zhi. 39: 617-620Tang XF Wang J Zhang JH Meng XM Xu B Bin Qiao S et al.

Effect of the CYP2C19*2 and*3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.

Eur J Clin Pharmacol. 69: 1103-1112https://doi.org/10.1007/s00228-012-1446-8Tiroch KA Sibbing D Koch W Roosen-Runge T Mehilli J Schömig A et al.

Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events.

Am Heart J. 160: 506-512https://doi.org/10.1016/j.ahj.2010.06.039Tomek A Mat'oska V Frýdmanová A Magerová H Srámek M Paulasova-Schwabová J et al.

Impact of CYP2C19 polymorphisms on clinical outcomes and antiplatelet potency of clopidogrel in caucasian poststroke survivors.

Am J Ther. 25: E202-E212https://doi.org/10.1097/MJT.0000000000000416Tornio A Flynn R Morant S Velten E Palmer CNA MacDonald TM et al.

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.

Clin Pharmacol Ther. 103: 281-286https://doi.org/10.1002/cpt.780Trenk D Hochholzer W Fromm MF Chialda LE Pahl A Valina CM et al.

Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents.

J Am Coll Cardiol. 51: 1925-1934https://doi.org/10.1016/j.jacc.2007.12.056Tuteja S Glick H Matthai W Nachamkin I Nathan A Monono K et al.

Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention: A pragmatic randomized clinical trial.

Circ Genomic Precis Med. https://doi.org/10.1161/CIRCGEN.119.002640Sun W Li Y Li J Zhang Z Zhu W Liu W et al.

Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.

Platelets. 26: 558-562https://doi.org/10.3109/09537104.2014.953044Wallentin L James S Storey RF Armstrong M Barratt BJ Horrow J et al.

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial.

Lancet. 376: 1320-1328https://doi.org/10.1016/S0140-6736(10)61274-3Wang Y Zhao X Lin J Li H Johnston SC Lin Y et al.

Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack.

JAMA - J Am Med Assoc. 316: 70-78https://doi.org/10.1001/jama.2016.8662Worrall A Armesilla A Norell M.

The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as measured by the Verify Now P2Y12 near-patient testing device in patients undergoing coronary angiography [abstract P2089].

Eur Heart J. 30: 327Han Y Lv HH Liu X Dong Q Yang XL Li SX et al.

Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outco